GLP1R and Insulin resistance: These previously defined actions of RANKL on inducing insulin resistance may be linked to our finding that DMAb reduced circulating DPP4 and increased GLP-1 levels, in that both DPP4 inhibitors54 and GLP-155 may also reduce insulin resistance.